Skip to main content
Premium Trial:

Request an Annual Quote

Biocept FGFR1 Blood Test

Biocept has launched blood-based FGFR1 amplification testing as a tool that doctors can use to discern which patients might benefit from certain breast and lung cancer therapies. Studies have implicated FGFR1 amplification as a driver of breast, non-small cell, and small cell lung cancers, and clinical trials are investigating treatments targeting this pathway.

FGFR1 testing is part of Biocept's portfolio of liquid biopsy tests for monitoring disease resistance and personalizing treatments for patients who don't have enough tissue from tumor biopsies. The molecular diagnostic firm's platform analyzes circulating tumor DNA in circulating tumor cells and plasma. Biocept markets OncoCEE-GA for gastric cancer, OncoCEE-BR for breast cancer and OncoCEE-LU for non-small cell lung cancer.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.